Related Experiment Video
Updated: May 19, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Evolving Strategies in HBV Management: Insights From Updated International Guidelines
Masaru Enomoto1,2, Grace Lai-Hung Wong3, Rui Huang4,5
1Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Summary
Updated international guidelines for chronic hepatitis B virus (HBV) infection expand treatment eligibility and explore finite nucleos(t)ide analogue (NA) therapy. Key shifts include risk-based assessment and emerging biomarkers, though treatment withdrawal recommendations vary.
Area of Science:
- Hepatology
- Virology
- Clinical Guidelines
Background:
- International guidelines for chronic hepatitis B virus (HBV) infection are evolving.
- New evidence impacts disease monitoring and antiviral treatment strategies.
Purpose of the Study:
- To summarize recent updates in 2024-2025 international HBV guidelines.
- To highlight changes in treatment eligibility, biomarker use, and finite therapy concepts.
Main Methods:
- Analysis of 2024-2025 guidelines from WHO, EASL, and AASLD.
- Comparison of recommendations on treatment criteria, biomarkers, and nucleos(t)ide analogue (NA) therapy duration.
Main Results:
- Treatment eligibility is expanding beyond traditional thresholds, incorporating fibrosis stage, age, and risk.
- Emerging biomarkers (HBsAg, HBV RNA, HBcrAg) are gaining attention for disease stratification.
- Recommendations on finite NA therapy and treatment withdrawal differ significantly among guidelines.
Conclusions:
- Updated HBV guidelines show convergence and controversy in management strategies.
- Understanding guideline differences is crucial for clinical practice and future research towards functional cure.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:23Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...